TRANSLATE

The lym Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the lym Hub cannot guarantee the accuracy of translated content. The lym and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

The Lymphoma & CLL Hub is an independent medical education platform, sponsored by Beigene, Johnson & Johnson and Roche, and supported through educational grants from Bristol Myers Squibb, Incyte, Lilly, and Pfizer. View funders.

Now you can support HCPs in making informed decisions for their patients

Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.

Find out more

Fixed-duration ibrutinib + venetoclax receives EC approval as first-line treatment for chronic lymphocytic leukemia

By Bryan Mc Swiney

Share:

Aug 5, 2022

Learning objective: After reading this article, learners will be able to cite a new clinical development in CLL.


On August 4, 2022, it was announced that the European Commission (EC) had granted approval to ibrutinib, a Bruton’s tyrosine kinase inhibitor, in combination with venetoclax, a BCL-2 inhibitor, as an oral fixed-duration regimen for the treatment of adult patients with previously untreated chronic lymphocytic leukemia (CLL). The approval is based on key data obtained from the phase III GLOW and phase II CAPTIVATE clinical trials (NCT03462719; NCT02910583).1

The GLOW trial reported a superior progression-free survival for ibrutinib + venetoclax over chlorambucil-obinutuzumab in elderly and unfit adult patients with CLL. The CAPTIVATE trial showed that treatment with ibrutinib + venetoclax led to deep and durable responses in patients ≤70 years of age with previously untreated CLL.

References

Please indicate your level of agreement with the following statements:

The content was clear and easy to understand

The content addressed the learning objectives

The content was relevant to my practice

I will change my clinical practice as a result of this content